At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 5, 2026 at 08:50 ET
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.
- IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
- Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
- 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
- NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access